R. Penson
4 Papers
R. Penson is an academic researcher. The author has contributed to research in topics: Internal medicine & Olaparib. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Jean-Sebastien Frenel,J. Kim,Nanda R. Aryal,Rebecca Asher,Dominique L. Berton,Laura Vidal,Patricia Pautier,Jonathan A. Ledermann,R. Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Sandro Pignata,N. Colombo,Tjoung-Won Park-Simon,Kenji Tamura,GS Sonke,Alison Freimund,C.K. Lee,Eric Pujade-Lauraine +19 more
TL;DR: In the SOLO2 trial as mentioned in this paper , maintenance olaparib in patients with relapsed ovarian cancer (PSROC) and BRCA mutation significantly improved progression-free survival (PFS) and prolonged overall survival (OS).
92
529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Shantimoy Banerjee,Martina Imbimbo,Patricia Roxburgh,J. Kim,M. Kim,Ruth Plummer,S.M. Stemmer,B. You,M. Ferguson,R. Penson,David M. O'Malley,K. Meyer,H. F. Gao,Helen K. Angell,A. Tablante Nunes,S. Domchek,Yvette Drew +16 more
TL;DR: The MEDIOLA (NCT02734004) study evaluated the efficacy and safety of olaparib+durvalumab (O+D doublet cohort) and O+D+bevacizumab(O +D+B triplet cohort), in patients with non-germline BRCA-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) as mentioned in this paper .
21
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Kyle Francis,S. I. Kim,Michael Friedlander,Val Gebski,Isabelle Ray-Coquard,A. Clamp,R. Penson,Aabha Oza,Tamar Perri,Tomasz Huzarski,Cristina Martin-Lorente,Sabrina Chiara Cecere,N. Colombo,Beyhan Ataseven,Keiichi Fujiwara,GS Sonke,Ignace Vergote,Eric Pujade-Lauraine,J. Kim,C.K. Lee +19 more
TL;DR: In this paper , the authors used data from the SOLO2 trial to evaluate the impact of dose alterations on survival outcomes and identified baseline characteristics associated with dose alteration, including adverse event (AE)-associated olaparib interruption, dose reduction, and discontinuation in 50, 28, and 17% of patients.
19
LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3
Charles Leath Iii,Giovanni Scambia,R Villalobos,Nicoletta Colombo,David Cibula,Mariusz Bidziński,Jae-Weon Kim,Joo-Hyun Nam,Radosław Mądry,Carlos Hernandez Hernandez,Paulo Alexandre Ribeiro Mora,Sang Young Ryu,Mei Lin W. Ah-See,Elizabeth S. Lowe,Natalia Lukashchuk,Dave Carter,R. Penson +16 more
- 01 Dec 2022
TL;DR: In the open-label Phase III SOLO3 trial (NCT02282020), olaparib treatment improved objective response rate (primary endpoint) and progression-free survival, versus single-agent non-platinum chemotherapy treatment of physician's choice (TPC), in patients with germline BRCA1 and/or bRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) with ≥2 prior lines of platinum-based chemotherapy as discussed by the authors .